Nymox Pharmaceutical’s NX-1207 Offers a New and Attractive Approach to the Treatment of Benign Prostatic Hyperplasia

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) provided an outline today of the outstanding potential the Company’s proprietary drug, NX-1207, has for the treatment of the common condition of enlarged prostate or benign prostatic hyperplasia (BPH).
MORE ON THIS TOPIC